ArticleScientific reports2025
Integrated serological surveillance for neglected tropical diseases, vaccine-preventable diseases, and arboviruses in Samoa, 2018.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A multiplex serological assay for quantification of arbovirus antibody kinetics and neutralizing antibodies.PLoS neglected tropical diseases · 2026Article
- Qualitative risk assessment of Japanese encephalitis virus introduction and transmission in Pacific Island countries and territories.PLoS neglected tropical diseases · 2026Article
- Multi-pathogen serosurveillance in Tonga examining demographic correlates and geographic clustering of 17 pathogens.Scientific reports · 2026Article
- Navigating evidence-informed decision making for arboviral disease control in Pacific Island countries.BMC global and public health · 2026Review
- Comparison of an integrated versus stand-alone approach to post-validation surveillance for lymphatic filariasis in Niue: a micro-costing study, 2025.Journal of global health · 2026Article
- The Second Silent Pandemic: Why Arboviruses Demand an Orchestrated Global Health Response.Pathogens (Basel, Switzerland) · 2026Review
- Finding the Gaps: Integrated Serosurveillance and Spatial Clustering of Vaccine Preventable Diseases in Samoa, 2018-2019.Tropical medicine and infectious disease · 2025Article
- A Multiplex Serological Assay for the Detection of Antibody Responses to Arboviruses.Journal of visualized experiments : JoVE · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiplex bead immunoassays (MBA) can detect antibody responses to multiple antigens. Using MBA data from the Surveillance and Monitoring to Eliminate Lymphatic Filariasis (LF) and Scabies from Samoa (SaMELFS) 2018, we aim to estimate national seroprevalence of neglected tropical diseases (NTDs), vaccine-preventable diseases (VPDs), and arboviruses in Samoa. A community-based serosurvey of 3851 participants aged ≥ 5 years in 35 primary sampling units (PSUs). Using MBA, dried blood spots were assayed for antibodies (Ab) from 10 pathogens: LF, trachoma, yaws, tetanus, diphtheria, rubella, measles, dengue, Zika, and chikungunya. Seroprevalence was adjusted for study design, age, and gender. NTD seroprevalence for LF was 50.8% (Bm33 Ab), 32.0% (Wb123 Ab), 20.3% (Bm14 Ab); 5.5% for trachoma; and 1.0% (Tmpa Ab) and 0.2% (Rp17 Ab) for yaws. VPD seroprevalence was 91.0% for tetanus, 83.5% for diphtheria, 79.0% for rubella, and 43.6% for measles. Arbovirus seroprevalence for dengue was 91.1% (dengue virus serotype-1 [DENV-1]), 97.2% (DENV-2), 96.9% (DENV-3), 94.7% (DENV-4); 85.7% for Zika; and 57.0% for chikungunya. Increasing age was associated with seropositivity to NTDs, arboviruses, tetanus, and measles. Clustering was highest at the household level; the strongest clustering was for DENV-3 (intraclass correlation coefficient [ICC]:0.32), Bm33 Ab (ICC:0.31), and Bm14 Ab (ICC:0.31). Integrated serosurveillance can provide a comprehensive picture of population-level immunity to multiple diseases. Our investigation into associations with seroprevalence can aid the development of evidence-based prevention, control, and elimination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.